

## Prof. Dr. med. Björn Chapuy

Date prepared October 13, 2022  
Date of Birth June 12, 1977  
Gender/Family Male, married, two daughters (7 & 7)  
Work address Charité, University Medical Center Berlin  
Campus Benjamin Franklin  
Hematology, Oncology and Tumorimmunology  
Hindenburgdamm 30  
12203 Berlin  
Phone + 49 (0) 30 450 613423  
E-Mail: [bjorn.chapuy@charite.de](mailto:bjorn.chapuy@charite.de)  
Current Position Professor (W3, lifelong), Lead attending and  
Section head lymphoma



### Academic education

1997-2004 **Medical School**, UMG, German

### Scientific degrees

2021 **Univ. Prof.** (W3, lifelong), Charité, University Medical Center Berlin  
2020 **Board Certification**, Internal Medicine, Hematology and Oncology  
2018 **Univ. Prof.** (W2, tenure track), UMG  
2012 **Junior Faculty/Instructor** in Medicine, Dana-Farber Cancer Institute/Harvard Medical School (DFCI/HWS), Boston, MA, USA  
2006 **MD thesis (Dr. med.)**, Department of Biochemistry/Cell Biology (Prof. von Figura/ Prof. S. Höning), UMG (*Summa cum laude*)  
2004 **Unlimited License** to practice medicine in Germany  
2004 **Graduation** from Medical School, UMG

### Professional career

Since 2021 **Professor** of Translational Lymphoma Biology (W3), **Lead attending** and **Section head lymphoma**, Campus Benjamin Franklin, Charité – University Medicine Berlin, Berlin, Germany  
Since 2021 **Elected Speaker**, Aggressive Lymphoma working group, GLA  
Since 2021 **Attending**, Hematology and Medical Oncology, UMG  
Since 2019 **Steering board member**, German Lymphoma Alliance (GLA)  
2019 - 2021 **Member**, Research Council and Mice Facility Control Council, UMG  
2019 **Organizing Team**, DGHO (German Society of Hematology) meeting  
Since 2018 **Program Committee**, Aggressive Lymphoma, DGHO  
2018 - 2021 **Coordination team**, Else Kröner-Fresenius MD Program (Promtionskolleg), UMG  
Since 2018 **Associate Professor** of Tumor Biology and Signal Transduction (W2tt), UMG  
2016-2017 Declined Assistant Professor positions at Harvard Medical School (Boston, MA, USA) and MD Anderson Cancer Center (Houston, TX, USA) and Associate Professor (W2-Ruf) at Charité, Berlin, Germany  
Since 2014 **Ad hoc Reviewer**, grants, meetings and manuscripts  
2012-2018 **Junior Faculty/Instructor** in Medicine, with Prof. Dr. M. Shipp Lymphoma Program, DFCI/HMS, Boston, MA, USA  
Since 2009 **Affiliated Member**, Broad Institute, Cambridge, MA, USA  
2008 -2012 **Postdoctoral fellow** with Prof. Dr. M. Shipp, Lymphoma Program, DFCI/HWS, Boston, MA, USA  
2004-2008 **Research Associate** with Prof. Dr. G. Wulf, Department of Hematology and Oncology, UMG  
2004 -2008 **Combined residency and clinical fellowship** in Hematology and Oncology, Dept. of Hematology and Oncology (Prof. L. Trümper), UMG

## Awards

2021 and 2018	<b>Oncology Award</b> , Gilead Science GmbH
2016	<b>Medical Oncology Translational Grant Award</b> , DFCI/HWS
2014	<b>Claudia Adams Barr Award for Basic Cancer Research</b> , DFCI/HWS
2012 - 2015	<b>American Society of Hematology Achievement Award</b> (each year)

## Important Publications

1. **Chapuy B\***, Stewart C\*, Dunford AJ\*, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, Redd R, Cote CM, Ducar MD, Thorner AR, Rodig SJ, Getz G, Shipp MA. Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. *Blood*. 2019 Dec 26;134(26):2369-82.
2. **Chapuy B\***, Stewart C\*, Dunford A\* (\* denotes equal contribution), Kim J, Kamburov A, Redd R, Lawrence M, Roemer MGM, Li AJ, Ziepert M, Wala J, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin C, Hess J, Pedomallu C, Livitz D, Rosenbrock D, Rosenberg M, Tracy A, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson M, Golub TR, Beroukhir R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg D, Loeffler M, Pfreundschuh M, Trümper L, Getz G\*, Shipp MA\*. 2018. Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Out-comes. *Nat Med*. May;24(5):679-90.
3. **Chapuy B\***, Roemer MGM\* (\*=equal contributions), Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusen-leitner D, Linden E, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon K, Ferry, JA, Freeman G, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA. 2016. Targetable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. *Blood*. Feb 18;127(7):869-81.
4. **Chapuy B\***, Cheng H\* (\*=equal contributions), Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MGM, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. 2016. Diffuse Large B-cell Lymphoma Patient-derived Xenograft Models Capture the Molecular and Biologic Heterogeneity of the Disease. *Blood*. May 5;127(18):2203-13.
5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattray D, Freeman GJ, Rodig SJ, **Chapuy B**, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. 2015. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *N. Engl. J Med*. Jan 22;372(4):311-9.
6. Karreth FA, Reschke M, Ruocco A, Ng C, **Chapuy B**, Léopold V, Sjöberg M, Keane TM, Verma A, Ala U, Tay Y, Seitzer N, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP. 2015. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. *Cell*. Apr 9;161(2):319-32.
7. Lane AA, **Chapuy B**, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu S, Liu H, Yoda A, Alexe G, Schinze AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris M, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM. 2014. Chr.21q22 triplication contributes to B cell trans-formation through HMGN1 and loss of H3K27me3. *Nat Genet*. Jun;46(6):618-23.
8. **Chapuy B\***, McKeown MR\* (\*=equal contributions), Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun H, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. 2013. Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma. *Cancer Cell*. Dec 9;24(6):777-90.
9. Monti S\*, **Chapuy B\*** (\*=equal contributions), Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Curie T, Dogan A, Kutok JL, Beroukhir R, Neuberg D, Habermann T, Getz G, Kung AL, Golub TR, Shipp MA. 2012. Integrative Analysis Reveals an Outcome-associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B-cell Lymphoma. *Cancer Cell*. Sep 11;22(3):359-72.
10. Duan S\*, Cermak L\* , (\*=equal contributions), Pagan J, Rossi M, Francia di Celle P, **Chapuy B**, Shipp B, Chiarle R, Pagano M. 2012. The F-box protein FBXO11 targets BCL6 for degradation and is mutated in Diffuse Large B-Cell Lymphomas, leading to BCL6 stabilization. *Nature*. Jan 5;481(7379):90-3.